| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-12-17 | Roche (Switzerland) Ocera Therapeutics (USA) | Macrocyclic Template Chemistry (MATCH™) discovery platform | licensing |
Technology - Services | Licensing agreement | |
| 2013-12-12 | Roche (Switzerland) Prothena (Ireland) | antibodies that target alpha-synuclein, including PRX002 | Parkinson\'s disease | R&D |
Neurodegenerative diseases | R&D agreement |
| 2013-12-11 | Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | Lu AF20513 | Alzheimer\'s disease | R&D |
Neurodegenerative diseases | R&D agreement |
| 2013-12-11 | Medimmune (USA - global biologics arm of AstraZeneca (UK) Johns Hopkins University (USA) | cardiovascular diseases, metabolic diseases, oncology, respiratory diseases inflammation and autoimmunity; infectious disease and neuroscience | R&D |
Cardiovascular diseases - Metabolic diseases - Respiratory diseases - Inflammatory diseases - Autoimmune diseases - Cancer - Oncology - Infectious diseases - CNS diseases. | R&D agreement | |
| 2013-12-11 | BioWa (Japan) Lonza (Switzerland) Medimmune (USA - global biologics arm of AstraZeneca (UK) | POTELLIGENT® CHOK1SV | licensing |
Technology - Services | Licensing agreement | |
| 2013-12-11 | GSK (UK) Inserm Transfert (France) | therapeutic antibodies targeting an immune checkpoint molecule such as ICOS (Inducible T-cell COStimulator) | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-12-10 | Antitope (UK) Annexon (USA) | antibody therapeutics for the treatment of neurodegenerative diseases | neurodegenerative diseases | R&D |
Neurodegenerative diseases | R&D agreement |
| 2013-12-10 | Theranexus (France) CEA (France) Bio-Modeling-Systems (France) | agents capable of altering the therapeutic effect of psychotropic substances (anti-depressants, anti-psychotics, psycho-stimulants, etc.) | licensing |
CNS diseases - Mental diseases | Licensing agreement | |
| 2013-12-09 | Adocia (France) CNRS (France) the University Bordeaux I (France) Institut Polytechnique de Bordeaux (France) Aquitaine Science Transfert (SATT Aquitaine - France) | DriveIn® (nanotechnology for drug delivery) | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-12-06 | Biocartis (Belgium) VIB (Belgium) | microsatellite instability (MSI) biomarkers | several cancers including colorectal cancer and ovarian cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2013-12-05 | The Lead Discovery Center (LDC) (Germany) Bayer (Germany) | undisclosed lead structure | licensing |
Cancer - Oncology | Milestone | |
| 2013-12-05 | Lysogene (France) Regenx Biosciences (USA - MD) | rAAVrh10 vectors | mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome Type A) | development |
Rare diseases | Development agreement |
| 2013-12-04 | Sirona Biochem (Canada) Bloom Burton & Co (Canada) | inflammation, infectious diseases | development |
Infectious diseases - Inflammatory diseases - Rare diseases | Joint-venture agreement | |
| 2013-12-04 | Lucane Pharma (France) Medunik Canada (Canada) | urea cycle disorder | collaboration |
Rare diseases - Genetic diseases - Metabolic diseases - Liver diseases | Collaboration agreement | |
| 2013-12-04 | Teva Pharmaceutical Industries (Israel) Takeda Pharmaceutical (Japan) | Copaxone® (glatiramer acetate) | multiple sclerosis | licensing |
Autoimmune diseases - Neurodegenerative diseases | Licensing agreement |
| 2013-12-04 | Leukocare (Germany) undisclosed top-tier global provider of animal health products | SPS (Stabilizing and Protecting Solutions) technology platform for veterinarian vaccine | undisclosed infectious disease | licensing |
Veterinary medicine | Licensing agreement |
| 2013-12-03 | Royal DSM (The Netherlands) Tunitas Therapeutics (USA) | Fc-fusion protein for the treatment of asthma and other allergic diseases | asthma, other allergic diseases | development |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Production agreement |
| 2013-12-03 | Protagen (Germany) Pfizer (USA - NY) | prediction or patient stratification markers | R&D |
Allergic diseases - Inflammatory diseases | R&D agreement | |
| 2013-12-03 | CMC Biologics (Denmark - USA) University of Copenhagen (Denmark) | antigen VAR2CSA for a placental malaria vaccine | malaria | development |
Infectious diseases - Parasitic diseases | Production agreement |
| 2013-12-03 | Biotest (Germany) EpiVax (USA -RI) | non-immunogenic Factor VIII (FVIII) | hemophilia A | R&D |
Hematologic diseases - Genetic diseases - Rare diseases | R&D agreement |
